Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2

Pujante, Pedro; Blanco, Jessica Ares; Maciá, Carmen; Escobedo, Raúl Rodríguez; Menéndez, Edelmiro; Delgado, Elías

doi:10.1016/j.medcli.2018.09.019

Cited by 2 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25,38 Ten studies reported no episodes of major hypoglycemic events. 25-32,36,39 No statistically significant differences in hypoglycemia were reported between SGLT2 inhibitor groups and placebo. Urinary tract infections (UTIs) and genital injections (GTIs) events were infrequently observed in the majority of studies.…”

Section: Resultsmentioning

confidence: 95%

“…After stratification based on A1c, there was a statistically significant decrease in insulin dose for patients with A1c of less than 7.5%, but there was no statistically significant decrease for the patients with an A1c of 7.5% to 8.5% or A1c >8.5%. 27…”

Section: Resultsmentioning

confidence: 99%

“…Urinary tract infections (UTIs) and genital injections (GTIs) events were infrequently observed in the majority of studies. 25-31,34,35,38,39 In 2 studies, a higher incidence of UTIs or GTI was noted, but of similar incidence between active and placebo arms. 32,33 However, two studies did report a significantly higher incidence of GTIs in active compared with placebo groups.…”

Section: Resultsmentioning

confidence: 99%

“…In the 16-week retrospective study conducted by Pujante et al, patients with an average A1c of 8.3% (range = 5.9%-11.5%) were stratified into subgroups based on baseline A1c. 27 The greatest decrease in TDI from baseline was in the baseline A1c of <7.5% subgroup. This may suggest that the largest impact is seen in patients with lower baseline A1c values, but more research is needed to further explore this concept.…”

Section: Relevance To Patient Care and Clinical Practicementioning

confidence: 88%

See 3 more Smart Citations

A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes

et al. 2022

View full text Add to dashboard Cite

Objective Assess evidence describing the effect of Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors on total daily insulin (TDI) requirements in insulin-dependent patients with type 2 diabetes. Data sources A scoping review was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Protocols and Scoping Reviews (PRISMA-ScR) guidelines. The search was conducted in PubMed; citation mapping was completed in Web of Science. Filters for human studies, English language, and a publication date, from January 1, 2005 to April 12, 2021, were applied. Study selection and data extraction Studies assessing insulin dose requirements with concurrent use of an SGLT2 inhibitor for patients with type 2 diabetes were included. Data synthesis Sixteen studies were included and demonstrated that addition of an SGLT2 inhibitor typically reduced TDI requirements. Insulin reductions were often statistically significant, occurring in studies evaluating (1) within subjects who received SGLT2 inhibitors, and (2) between subjects receiving SGLT2 inhibitors versus placebo. Compared with placebo, insulin dose reduction ranged from −0.72 to −19.2 units. However, studies were relatively small, not designed to assess TDI change, and some utilized fixed dose insulin protocols or empiric insulin dose reductions. Conclusions Lowering insulin requirements may have benefits, such as decreased hypoglycemia risk, insulin resistance, and cost. Addition of an SGLT2 inhibitor may modestly reduce TDI requirements for patients with type 2 diabetes. Evidence indicating SGLT2 inhibitor use reduces TDI may lead to additional implementation in practice and inform future research. Further research is needed to clarify insulin type (i.e., basal or prandial) and degree of TDI reduction expected with addition of an SGLT2 inhibitor.

show abstract

Section: Resultsmentioning

confidence: 95%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Relevance To Patient Care and Clinical Practicementioning

confidence: 88%

See 2 more Smart Citations

A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes

et al. 2022

View full text Add to dashboard Cite

show abstract

“…24 Based on four months follow-up, a study reported 0.7 % HbA1c reduction, weight dropped for an average −2.0 kg, SBP dropped significantly, but no change in DBP were observed. 25…”

Section: Discussionmentioning

confidence: 99%

A 12 week prospective clinical evidence of empagliflozin efficacy in uncontrolled type 2 diabetes mellitus treated with metformin and a sulfonylurea

Puli¹,

Vanjari²

2019

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: The main aim of the study is to evaluate the efficacy of empagliflozin 10 mg once daily over 12 weeks as add-on therapy to metformin plus sulfonylurea in patients with type 2 diabetes mellitus with inadequate glycemic control.Methods: It is a prospective, observational, study conducted in patients of Sri Badhrakali Diabetic Center located in Warangal, Telangana, India. The efficacy of empagliflozin 10 mg was assessed by measuring the change in the glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), body mass index (BMI) at the baseline and 12 weeks, systolic blood pressure (SBP) and diastolic blood pressure (DBP) at the baseline and after 24 hours of treatment.Results: In the present study, the addition of empagliflozin to metformin and Sulfonylurea therapy for 12 weeks provided 0.87 % reduction in HbA1c. The mean changes of FPG from baseline to 12-week is -26 mg/dl. At 24 hours empagliflozin significantly reduced blood pressure with mean changes of SBP and DBP -4.147 and -1.526 mmHg respectively. The mean changes in BMI from baseline to week 12 is -0.638 kg/m2.Conclusions: Empagliflozin 10 mg provided ancillary reduction in HbA1c outside of metformin and sulfonylurea. Controlled body weight, HbA1c, blood pressure decreases diabetes progression, decreased risk of diabetic complications and reduced risk for cardiovascular disorders.

show abstract

Efficacy of sodium glucose cotransporter 2 inhibitors as an adjunct treatment for patients with diabetes type 2

Cited by 2 publications

References 6 publications

A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes

A Scoping Review Evaluating the Effect of SGLT-2 Inhibitors on Insulin Dose Requirements in Insulin-Dependent Patients With Type 2 Diabetes

A 12 week prospective clinical evidence of empagliflozin efficacy in uncontrolled type 2 diabetes mellitus treated with metformin and a sulfonylurea

Contact Info

Product

Resources

About